"Patients with metastatic hormone-sensitive prostate cancer benefited from treatment with darolutamide plus ADT and docetaxel ...

The pCR was 37.3% (95% CI, 33.2-41.6) in the durvalumab arm and 27.5% (95% CI, 23.8-31.6) in the comparator arm.

A total of 37 studies included real-world OS as an outcome; in these studies, median real-world OS ranged from 9 months to 23 ...

Avelumab plus BSC significantly prolongs OS and PFS in advanced urothelial carcinoma, regardless of diabetes mellitus status. The study included 700 patients, with a balanced distribution of diabetes ...

Casdatifan showed promising clinical activity in clear cell RCC, with response rates between 25% and 33% across dosage cohorts. The 100 mg/day dosage of casdatifan is planned for future combination ...

“Interestingly, the confirmed response rate in the intention to treat population was 32%, but this increases to 53% in the MET driven subset,” says Francesca Jackson-Spence, MBChB, BMedSc, MRCP. In ...

ORR was 70% (95% CI, 55-82) in cohort 1 compared with 31% (95% CI, 19-45) in cohort 2. Durable antitumor activity continued to be seen with combination treatment with belzutifan (Welireg) plus ...

“Taken altogether, the study remains positive for PFS, but not for overall survival,” says Laurence Albiges, MD, PhD. In this video, Laurence Albiges, MD, PhD, shares final results from the phase 3 ...

"The median progression-free survival and median overall survival continue to be almost double what we see with chemotherapy," says Gopa Iyer, MD. In this video, Gopa Iyer, MD, shares findings from an ...

The MHRA has accepted the marketing authorization application for Anktiva combined with BCG for BCG-unresponsive NMIBC with CIS in the UK. Anktiva received FDA approval in the US in April 2024, and ...

Radium-223 re-treatment in mCRPC patients shows a low incidence of hematologic and non-hematologic adverse events, including skeletal-related events. The study reported a median overall survival of 16 ...